Navigation Links
Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
Date:6/30/2008

tamine is a highly addictive stimulant that affects the central nervous system. Abuse of the drug leads to devastating medical, psychological and social consequences.

According to the 2005 SAMHSA Survey on Drug Use and Health, an estimated 10.4 million people age 12 or older (4.3 percent of the population) have tried methamphetamine at some time in their lives. Approximately 1.3 million reported past-year methamphetamine use, and 512,000 reported current (past-month) use. Approximately 535,000 patients sought treatment for methamphetamine and other stimulant abuse in 2006. In addition, according to the 2006 SAMHSA Survey, an estimated 22.6 million people in the United States suffered from dependence on illicit drugs.

According to the Office of National Drug Control Policy, the costs of drug abuse to society were an estimated $180 billion in 2002 in the United States. According to the United Nations Office on Drugs and Crime, in 2005 there were approximately 4.1 million users of cocaine and 2.8 million users of amphetamine-type stimulants across Europe.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... HDT Engineered Technologies (HDT), a leader ... a principal subcontractor for the mechanical development of ... new anthropromorphic arm technology that will give patients ... hand, including a sense of touch. ,, ... Agency (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the ...
(Date:12/16/2009)... DATATRAK International, Inc. (OTCQX: DATA), ... global eClinical solutions for the clinical trials ... version 9.0 eClinical Software. This release ... and service delivery and introduces two new ... the DATATRAK Learning Center(TM) and the DATATRAK ...
(Date:12/16/2009)... Iceland, December 16 Scientists at,deCODE genetics, ... Nature the,discovery of a version of a common ... (SNP) with a major impact on susceptibility to ... variant is not only large, but unusual:,if an ... increases risk of,T2D by more than 30% compared ...
Breaking Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4FertilityAuthority Introduces E Newsletter The Daily Shot 51744 1FertilityAuthority Introduces E Newsletter The Daily Shot 51744 2Passavant Area Hospital Adopts Quantros for Event Management and Reporting 51743 1Passavant Area Hospital Adopts Quantros for Event Management and Reporting 51743 2Passavant Area Hospital Adopts Quantros for Event Management and Reporting 51743 3KarenZupko 26amp 3B Associates Inc and ReachMD XM 160 Announce New Radio Programming Series 26quot 3BPractice Success 26quot 3B hosted by Karen 51741 1KarenZupko 26amp 3B Associates Inc and ReachMD XM 160 Announce New Radio Programming Series 26quot 3BPractice Success 26quot 3B hosted by Karen 51741 2KarenZupko 26amp 3B Associates Inc and ReachMD XM 160 Announce New Radio Programming Series 26quot 3BPractice Success 26quot 3B hosted by Karen 51741 3
... stent thrombosis after two years in,high-risk patient ... 22, 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,announced ... clinical,trial. The data demonstrated that the safety ... of the TAXUS(R),Express(TM) paclitaxel-eluting stent system -- ...
... Technology,Significantly Enhances Potency of Gene-Based Prostate Cancer,Vaccine ... Clinical Trial Using,Inovio’s Electroporation DNA Delivery Technology ... -- Inovio Biomedical Corp. (AMEX: INO),focused on ... and,infectious diseases and a novel alternative to ...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3Inovio: DNA delivery technology shows positive human results 2Inovio: DNA delivery technology shows positive human results 3Inovio: DNA delivery technology shows positive human results 4Inovio: DNA delivery technology shows positive human results 5Inovio: DNA delivery technology shows positive human results 6
(Date:12/16/2009)... Inc. (Nasdaq: SMBL ) announced today that its ... program of up to $25 million, to begin in ... have in the prospects of our Company and shows ... our shareholders, while at the same time making prudent ... Chairman and Chief Executive Officer. ,, Any purchases under ...
(Date:12/16/2009)... Ga., Dec. 16 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... board as a new independent director, effective January 1, ... blood banking and transfusion medicine for more than 30 ... Medicine at the University of Virginia School of Medicine. ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...
(Date:12/16/2009)... Coalition Urges Lawmakers to Ensure and Encourage Access to Quality, Cost-Effective ... ... -- For months, members of Congress have debated the best ways ... part of health care reform. An important part of the ... full range of health care providers besides doctors of medicine (MDs) ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5
... of the currently used multiple sclerosis drugs can be ... //. Previously, the same group of researchers had established ... lower the development of full-blown form of multiple sclerosis. ... documented in animal models of the disease, so far, ...
... to board a 500-capacity British cruise vessel, Funchal that has ... presently off the West Australian coast, and will host the ... board have been infected by a contagious flu. ,The ... said, "The Department of Health is sending a team of ...
... at the Medway Maritime Hospital in Kent has blasted the NHS ... since his hospital cannot afford to do more surgery. // ... person to turn up when there should be three in the ... - while we're paid, when we could be seeing patients," Dr ...
... in Mumbai and many more with the symptoms of the ... said that more doctors has been pressed into service to ... ,Around 50 people were admitted to hospitals Wednesday, particularly in ... count, 90 people were admitted to hospitals and five in ...
... common to feel down in the dumps, and under weather, when ... But there is a huge gap between feeling low and depression, ... one in every ten people in the United Kingdom, and falls ... to be more prone to depression., ,Depression is a ...
... man in central-western NSW, both suspected to have contacted meningococcal ... The man and the baby, who hail from Cobar and ... ,It has not been possible to relate both the ... Dr.Tony Brown of the Greater Western Area Health Service. In ...
Other Medicine News:Health News:Drug Combo Improves Performance Of Multiple Sclerosis Drug 2
... FiberStick, available in #2 or 2-0 sizes, ... waxed end. Used in conjunction with small ... needles, it makes suture passing easy. By ... it alleviates the need for a monofilament ...
... is a suture option for ... diameter looped FiberWire products allow ... extensor tendon repairs while reducing ... passes. FiberLoop is available with ...
... the Flowmaster. It is a new portable digital ... ease of use, simplicity and cost effectiveness are ... it now very easy to give a patient ... want and data will be send wirelessly to ...
... The Flowstar is a compact and ... flowstudies. The investigation starts automatically when ... and volume scales can be adjusted ... are user selectable. Siroky flow plots ...
Medicine Products: